Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 26;8(9):308.
doi: 10.3390/biomedicines8090308.

The Liquid Biopsy in the Management of Colorectal Cancer: An Overview

Marco Vacante  1 , Roberto Ciuni  1 , Francesco Basile  1 , Antonio Biondi  1
Affiliations
Review

The Liquid Biopsy in the Management of Colorectal Cancer: An Overview

Marco Vacante et al. Biomedicines. .

Abstract

Currently, there is a crucial need for novel diagnostic and prognostic biomarkers with high specificity and sensitivity in patients with colorectal cancer. A "liquid biopsy" is characterized by the isolation of cancer-derived components, such as circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs, and proteins, from peripheral blood or other body fluids and their genomic or proteomic assessment. The liquid biopsy is a minimally invasive and repeatable technique that could play a significant role in screening and diagnosis, and predict relapse and metastasis, as well as monitoring minimal residual disease and chemotherapy resistance in colorectal cancer patients. However, there are still some practical issues that need to be addressed before liquid biopsy can be widely used in clinical practice. Potential challenges may include low amounts of circulating tumor cells and circulating tumor DNA in samples, lack of pre-analytical and analytical consensus, clinical validation, and regulatory endorsement. The aim of this review was to summarize the current knowledge of the role of liquid biopsy in the management of colorectal cancer.

Keywords: biomarkers; circulating tumor DNA; circulating tumor cells; colorectal cancer; liquid biopsy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. GBD 2017 Colorectal Cancer Collaborators The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2019;4:913–933. doi: 10.1016/S2468-1253(19)30345-0. - DOI - PMC - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Bishehsari F., Mahdavinia M., Vacca M., Malekzadeh R., Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J. Gastroenterol. 2014;20:6055–6072. doi: 10.3748/wjg.v20.i20.6055. - DOI - PMC - PubMed
    1. Hui L. Quantifying the effects of aging and urbanization on major gastrointestinal diseases to guide preventative strategies. BMC Gastroenterol. 2018;18 doi: 10.1186/s12876-018-0872-1. - DOI - PMC - PubMed
    1. Valli A., Harris A.L., Kessler B.M. Hypoxia metabolism in ageing. Aging Albany N. Y. 2015;7:465–466. doi: 10.18632/aging.100782. - DOI - PMC - PubMed

LinkOut - more resources